KRAS and colorectal carcinoma: Recent findings showed that the combination of the mTOR inhibitor AZD8055 with ABT-263, an inducer of apoptosis, promoted cell death in CRC cell lines with KRAS or BRAF mutation [9], a timely result given CRC entities harboring these mutations are refractory to current targeted therapies.